P Carmeliet

Summary

Affiliation: Katholieke Universiteit Leuven
Country: Belgium

Publications

  1. ncbi Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms
    Ingeborg Stalmans
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Catholic University Leuven, Leuven, Belgium
    J Clin Invest 109:327-36. 2002
  2. ncbi Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1
    Aernout Luttun
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, University of Leuven, Leuven, Belgium
    Nat Med 8:831-40. 2002
  3. ncbi Manipulating angiogenesis in medicine
    Peter Carmeliet
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversitary Institute for Biotechnology, KU Leuven, Campus Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    J Intern Med 255:538-61. 2004
  4. ncbi Novel role for vascular endothelial growth factor (VEGF) receptor-1 and its ligand VEGF-B in motor neuron degeneration
    Koen Poesen
    Vesalius Research Center, Katholieke Universiteit Leuven, Leuven B 3000, Belgium
    J Neurosci 28:10451-9. 2008
  5. ncbi Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
    P Carmeliet
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Belgium
    Nature 394:485-90. 1998
  6. ncbi Tissue factor
    P Carmeliet
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Leuven, Belgium
    Int J Biochem Cell Biol 30:661-7. 1998
  7. ncbi Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188
    P Carmeliet
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Belgium
    Nat Med 5:495-502. 1999
  8. ncbi Mouse models of angiogenesis, arterial stenosis, atherosclerosis and hemostasis
    P Carmeliet
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Leuven, Belgium
    Cardiovasc Res 39:8-33. 1998
  9. ncbi The emerging role of the bone marrow-derived stem cells in (therapeutic) angiogenesis
    P Carmeliet
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversitary Institute for Biotechnology, KULeuven, Belgium
    Thromb Haemost 86:289-97. 2001
  10. ncbi Angiogenesis in health and disease
    Peter Carmeliet
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversitary Institute for Biotechnology, KULeuven, Campus Gasthuisberg, Herestraat 49, B 3000, Leuven, Belgium
    Nat Med 9:653-60. 2003

Detail Information

Publications144 found, 100 shown here

  1. ncbi Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms
    Ingeborg Stalmans
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Catholic University Leuven, Leuven, Belgium
    J Clin Invest 109:327-36. 2002
    ..These findings reveal distinct roles of the various VEGF isoforms in vascular patterning and arterial development in the retina...
  2. ncbi Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1
    Aernout Luttun
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, University of Leuven, Leuven, Belgium
    Nat Med 8:831-40. 2002
    ..Thus, PlGF and Flt1 constitute potential candidates for therapeutic modulation of angiogenesis and inflammation...
  3. ncbi Manipulating angiogenesis in medicine
    Peter Carmeliet
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversitary Institute for Biotechnology, KU Leuven, Campus Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    J Intern Med 255:538-61. 2004
    ..That such therapeutic strategies might change the face of medicine is witnessed by initial evidence of success in the clinic...
  4. ncbi Novel role for vascular endothelial growth factor (VEGF) receptor-1 and its ligand VEGF-B in motor neuron degeneration
    Koen Poesen
    Vesalius Research Center, Katholieke Universiteit Leuven, Leuven B 3000, Belgium
    J Neurosci 28:10451-9. 2008
    ..The neuroprotective activity of VEGF-B, in combination with its negligible angiogenic/permeability activity, offers attractive opportunities for the treatment of neurodegenerative diseases...
  5. ncbi Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
    P Carmeliet
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Belgium
    Nature 394:485-90. 1998
    ..As hypoxic stress contributes to many (patho)biological disorders, this new role for HIF-1alpha in hypoxic control of cell growth and death may be of general pathophysiological importance...
  6. ncbi Tissue factor
    P Carmeliet
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Leuven, Belgium
    Int J Biochem Cell Biol 30:661-7. 1998
    ..Elucidation of the mechanism of its action may provide insights for selective interference with the hemostatic versus morphogenic properties of tissue factor...
  7. ncbi Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188
    P Carmeliet
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Belgium
    Nat Med 5:495-502. 1999
  8. ncbi Mouse models of angiogenesis, arterial stenosis, atherosclerosis and hemostasis
    P Carmeliet
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Leuven, Belgium
    Cardiovasc Res 39:8-33. 1998
    ....
  9. ncbi The emerging role of the bone marrow-derived stem cells in (therapeutic) angiogenesis
    P Carmeliet
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversitary Institute for Biotechnology, KULeuven, Belgium
    Thromb Haemost 86:289-97. 2001
    ..These findings have raised hopes that bone marrow-derived cells might one day become useful for cell-based angiogenic therapy...
  10. ncbi Angiogenesis in health and disease
    Peter Carmeliet
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversitary Institute for Biotechnology, KULeuven, Campus Gasthuisberg, Herestraat 49, B 3000, Leuven, Belgium
    Nat Med 9:653-60. 2003
    ..Molecular insights into these processes are being generated at a rapidly increasing pace, offering new therapeutic opportunities that are currently being evaluated...
  11. ncbi Transgenic mouse models in angiogenesis and cardiovascular disease
    P Carmeliet
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Leuven, B 3000, Belgium
    J Pathol 190:387-405. 2000
    ..A selected number of molecules that have been studied in the authors' laboratory will be reviewed in more detail...
  12. ncbi Mechanisms of angiogenesis and arteriogenesis
    P Carmeliet
    The Center for Transgene Technology and Gene Therapy Flanders Interuniversity Institute for Biotechnology KU Leuven, Leuven, B 3000, Belgium
    Nat Med 6:389-95. 2000
    ....
  13. ncbi De novo vasculogenesis in the heart
    Aernout Luttun
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversitary Institute for Biotechnology, KU Leuven, B 3000, Leuven, Belgium
    Cardiovasc Res 58:378-89. 2003
    ....
  14. ncbi Molecular basis of angiogenesis. Role of VEGF and VE-cadherin
    P Carmeliet
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity, Belgium
    Ann N Y Acad Sci 902:249-62; discussion 262-4. 2000
    ..In addition, a novel interaction between the junctional protein vascular endothelial-cadherin (VE-cadherin) and VEGF, essential for the endothelial survival function of VEGF, will be reviewed...
  15. ncbi Angiogenesis in cancer and other diseases
    P Carmeliet
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Belgium
    Nature 407:249-57. 2000
    ..This integrated understanding is leading to the development of a number of exciting and bold approaches to treat cancer and other diseases. But owing to several unanswered questions, caution is needed...
  16. ncbi Receptor-independent role of urokinase-type plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice
    P Carmeliet
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Leuven, Belgium
    J Cell Biol 140:233-45. 1998
    ..Taken together, these results suggest that binding of u-PA to u-PAR is not required to provide sufficient pericellular u-PA-mediated plasmin proteolysis to allow cellular migration into a vascular wound...
  17. ncbi Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions
    P Carmeliet
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Leuven, Belgium
    Nat Med 7:575-83. 2001
    ..By upregulating PlGF and the signaling subtype of VEGFR-1, endothelial cells amplify their responsiveness to VEGF during the 'angiogenic switch' in many pathological disorders...
  18. ncbi Vascular and neuronal effects of VEGF in the nervous system: implications for neurological disorders
    Peter Carmeliet
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, University of Leuven, Belgium
    Semin Cell Dev Biol 13:39-53. 2002
    ..A challenge for the future is to unravel to what extent the effect of VEGF in these disorders relates to its angiogenic activity or direct neurotrophic effect...
  19. ncbi Blood vessels and nerves: common signals, pathways and diseases
    Peter Carmeliet
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Katholieke Universiteit Leuven, Campus Gasthuisberg, Herestraat 49, B 3000, Leuven, Belgium
    Nat Rev Genet 4:710-20. 2003
    ..The realization that both systems use common genetic pathways should not only form links between vascular biology and neuroscience, but also promises to accelerate the discovery of new mechanistic insights and therapeutic opportunities...
  20. ncbi Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis
    P Carmeliet
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Leuven, Belgium
    Cell 98:147-57. 1999
    ..Thus, VE-cadherin/ beta-catenin signaling controls endothelial survival...
  21. ncbi Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system
    P Carmeliet
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Belgium
    Ann N Y Acad Sci 811:191-206. 1997
    ..Thus, the plasminogen system significantly affects thrombosis, restenosis, and atherosclerosis...
  22. ncbi Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration
    B Oosthuyse
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Leuven, B 3000, Belgium
    Nat Genet 28:131-8. 2001
    ..Acute ischemia is known to cause nonselective neuronal death. Our results indicate that chronic vascular insufficiency and, possibly, insufficient Vegf-dependent neuroprotection lead to the select degeneration of motor neurons...
  23. ncbi Targeted deletion of the cytosolic domain of tissue factor in mice does not affect development
    E Melis
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology VIB, KU Leuven, Leuven, B 3000, Belgium
    Biochem Biophys Res Commun 286:580-6. 2001
    ....
  24. ncbi Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice
    N Nagai
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Center for Molecular and Vascular Biology, KU Leuven, Belgium
    Circulation 99:2440-4. 1999
    ....
  25. ncbi Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure
    S Heymans
    Center for Transgene Technology, Flanders Interuniversity, Leuven, Belgium
    Nat Med 5:1135-42. 1999
    ....
  26. ncbi Genetic analysis of the plasminogen and coagulation system in mice
    P Carmeliet
    Center for Transgene Technology and Gene Therapy, Vlaams Interuniversitair Instituut voor Biotechnologie, Leuven, Belgium
    Haemostasis 26:132-53. 1996
    ....
  27. ncbi Deficiency of urokinase-type plasminogen activator-mediated plasmin generation impairs vascular remodeling during hypoxia-induced pulmonary hypertension in mice
    M Levi
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, University of Leuven, Belgium
    Circulation 103:2014-20. 2001
    ..Chronic hypoxia results in the development of pulmonary hypertension and subsequent right heart failure. A role of the plasminogen system in the pathogenesis of pulmonary hypertension and pulmonary vascular remodeling has been suggested...
  28. ncbi Hypoxia-inducible factor-2alpha (HIF-2alpha) is involved in the apoptotic response to hypoglycemia but not to hypoxia
    K Brusselmans
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Leuven B-3000, Belgium
    J Biol Chem 276:39192-6. 2001
    ..Thus, HIF-1alpha and HIF-2alpha may have distinct roles in responses to environmental stress, and despite its name, HIF-2alpha may be more important in the survival response to environmental variables other than the level of oxygen...
  29. ncbi Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice
    P Carmeliet
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, University of Leuven, Belgium
    Circulation 96:3180-91. 1997
    ..Therefore, we studied the consequences of plasminogen activator inhibitor-1 (PAI-1) gene inactivation and adenoviral PAI-1 gene transfer on arterial neointima formation...
  30. ncbi Reduced transplant arteriosclerosis in plasminogen-deficient mice
    L Moons
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, B 3000 Leuven, Belgium
    J Clin Invest 102:1788-97. 1998
    ..These data indicate that plasmin proteolysis plays a major role in allograft arteriosclerosis by mediating elastin degradation, macrophage infiltration, media remodeling, medial smooth muscle cell migration, and formation of a neointima...
  31. ncbi Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes
    H R Lijnen
    Center for Molecular and Vascular Biology, University of Leuven, Belgium
    Arterioscler Thromb Vasc Biol 18:1035-45. 1998
    ....
  32. ncbi Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice
    P Carmeliet
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Leuven, Belgium
    Circ Res 81:829-39. 1997
    ..Thus, u-PA plays a significant role in vascular wound healing and arterial neointima formation after injury, most likely by affecting cellular migration...
  33. ncbi Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation
    P Carmeliet
    Centre for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, University of Leuven, Belgium
    Nat Genet 17:439-44. 1997
    ....
  34. ncbi Intestinal calcium transporter genes are upregulated by estrogens and the reproductive cycle through vitamin D receptor-independent mechanisms
    S J Van Cromphaut
    Laboratory of Experimental Medicine and Endocrinology LEGENDO, Katholieke Universiteit Leuven, Leuven, Belgium
    J Bone Miner Res 18:1725-36. 2003
    ..Estrogens and vitamin D are thus independent potent regulators of the expression of this calcium influx mechanism, which is involved in active intestinal calcium absorption...
  35. ncbi Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
    P Carmeliet
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Leuven, Belgium
    Nature 380:435-9. 1996
    ....
  36. ncbi Mice lacking factor VII develop normally but suffer fatal perinatal bleeding
    E D Rosen
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Leuven, Belgium
    Nature 390:290-4. 1997
    ..Thus, the TF-/- embryonic lethal and the FVII-/- survival-phenotypes suggest a role for TF during embryogenesis beyond fibrin formation...
  37. ncbi Restoration of thrombolytic potential in plasminogen-deficient mice by bolus administration of plasminogen
    H R Lijnen
    Center for Molecular and Vascular Biology, University of Leuven, Belgium
    Blood 88:870-6. 1996
    ..Thus, restoration of normal plasminogen levels in Plg-/- mice normalized the thrombolytic potential toward experimentally induced pulmonary emboli, and resulted in removal of endogenous fibrin deposits within 24 hours...
  38. ncbi Structure-function analyses of thrombomodulin by gene-targeting in mice: the cytoplasmic domain is not required for normal fetal development
    E M Conway
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, University of Leuven, Leuven, Belgium
    Blood 93:3442-50. 1999
    ..In conclusion, these studies exclude the cytoplasmic domain of TM from playing a role in the early embryonic lethality of TM-null mice and support its function in regulating plasmin generation in plasma...
  39. ncbi Replacement of the muscle-specific sarcoplasmic reticulum Ca(2+)-ATPase isoform SERCA2a by the nonmuscle SERCA2b homologue causes mild concentric hypertrophy and impairs contraction-relaxation of the heart
    M Ver Heyen
    Laboratories of Physiology, Flanders Interuniversity Institute for Biotechnology, Katholieke Universiteit Leuven, Belgium
    Circ Res 89:838-46. 2001
    ....
  40. ncbi Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis
    A Angelillo-Scherrer
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Leuven, Belgium
    Nat Med 7:215-21. 2001
    ..Thus, Gas6 is a platelet-response amplifier that plays a significant role in thrombosis. These findings warrant further evaluation of the possible therapeutic use of Gas6 inhibition for prevention of thrombosis...
  41. ncbi Blood coagulation factor X deficiency causes partial embryonic lethality and fatal neonatal bleeding in mice
    M Dewerchin
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Leuven, Belgium
    Thromb Haemost 83:185-90. 2000
    ....
  42. ncbi Generation and characterization of urokinase receptor-deficient mice
    M Dewerchin
    Center for Transgene Technology and Gene Therapy, Vlaams Interuniversitair Institut voor Biotechnologie, Leuven, Belgium
    J Clin Invest 97:870-8. 1996
    ..u-PAR-1- peritoneal macrophages had a threefold decreased initial rate of u-PA-mediated plasminogen activation in vitro but degraded extracellular matrix proteins in vitro as efficiently as u-PAR-1- macrophages...
  43. ncbi Factor VII deficiency rescues the intrauterine lethality in mice associated with a tissue factor pathway inhibitor deficit
    J C Chan
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, B 3000 Leuven, Belgium
    J Clin Invest 103:475-82. 1999
    ..5 and that any level of maternal FVII in early-stage embryos is insufficient to cause a coagulopathy in TFPIdelta/delta mice...
  44. ncbi Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice
    L R Jalbert
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, 3000 Leuven, Belgium
    J Clin Invest 102:1481-8. 1998
    ....
  45. ncbi Role of tissue factor in embryonic blood vessel development
    P Carmeliet
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Leuven, Belgium
    Nature 383:73-5. 1996
    ..Vitelline vessels from null mice were deficient in smooth-muscle alpha-actin-expressing mesenchymal cells, which participate in organization of the vessel wall. This implies that tissue factor has a role in blood vessel development...
  46. ncbi Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice
    Veerle Compernolle
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity, Institute for Biotechnology, Leuven, Belgium
    Nat Med 8:702-10. 2002
    ..The pneumotrophic effect of VEGF may have therapeutic potential for lung maturation in preterm infants...
  47. ncbi Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1
    Monica Autiero
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KULeuven, Leuven, B 3000, Belgium
    Nat Med 9:936-43. 2003
    ....
  48. ncbi Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188
    Christa Maes
    Laboratory of Experimental Medicine and Endocrinology, KU Leuven, B 3000, Leuven, Belgium
    Mech Dev 111:61-73. 2002
    ....
  49. ncbi Temporal and topographic matrix metalloproteinase expression after vascular injury in mice
    H R Lijnen
    Center for Molecular and Vascular Biology, University of Leuven, Belgium
    Thromb Haemost 81:799-807. 1999
    ..The temporal and topographic expression pattern of MMPs after vascular injury, coinciding with smooth muscle cell migration and neointima formation, thus is compatible with a role in vascular remodeling...
  50. ncbi Clinical and fundamental aspects of angiogenesis and anti-angiogenesis
    I Buysschaert
    Department for Transgene Technology and Gene Therapy, VIB, B 3000 Leuven, Belgium
    Acta Clin Belg 62:162-9. 2007
    ..This review discusses the different clinical trials of angiogenic inhibitors and stimulators, preceded by some fundamental aspects of angiogenesis, giving the clinician a brief overview of the most relevant angiogenic topics...
  51. ncbi Duodenal calcium absorption in vitamin D receptor-knockout mice: functional and molecular aspects
    S J Van Cromphaut
    Laboratory of Experimental Medicine and Endocrinology, Katholieke Universiteit Leuven, Leuven, B 3000 Belgium
    Proc Natl Acad Sci U S A 98:13324-9. 2001
    ....
  52. ncbi Loss of the VEGF(164) and VEGF(188) isoforms impairs postnatal glomerular angiogenesis and renal arteriogenesis in mice
    Virginie Mattot
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Belgium
    J Am Soc Nephrol 13:1548-60. 2002
    ..Thus, VEGF(164) and VEGF(188) not only mediate angiogenesis, but they also play an essential role in renal branching arteriogenesis...
  53. ncbi Abrupt rate accelerations or premature beats cause life-threatening arrhythmias in mice with long-QT3 syndrome
    D Nuyens
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Leuven, Belgium
    Nat Med 7:1021-7. 2001
    ..These results show the possible risk of sudden heart-rate accelerations. The Scn5a(Delta/+) mouse with its predisposition for pacing-induced arrhythmia might be useful for the development of new treatments for the LQT3 syndrome...
  54. ncbi Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders
    M Autiero
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, B-3000 Leuven, Belgium
    J Thromb Haemost 1:1356-70. 2003
    ..Thus, these preclinical studies show proof-of-principle that PlGF and VEGFR-1 are promising therapeutic targets to treat angiogenesis and inflammation related disorders. Clinical trials will reveal whether this is also true for patients...
  55. ncbi Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis
    P Carmeliet
    Center for Molecular and Vascular Biology, University of Leuven, Belgium
    J Clin Invest 92:2756-60. 1993
    ..Thus, disruption of the PAI-1 gene in mice appears to induce a mild hyperfibrinolytic state and a greater resistance to venous thrombosis but not to impair hemostasis...
  56. ncbi Development of targeted angiogenic medicine
    S Loges
    Vesalius Research Center, KU Leuven, Leuven, Belgium
    J Thromb Haemost 7:21-33. 2009
    ..In this review, we summarize recent developments and discuss questions that arise in the exciting, rapidly developing field of angiogenic medicine, including a brief description of its possible implications in neurodegenerative diseases...
  57. ncbi Antenatal fetal VEGF therapy to promote pulmonary maturation in a preterm rabbit model
    A Debeer
    Centre for Surgical Technologies, Faculty of Medicine, KU Leuven, Leuven, Belgium
    Early Hum Dev 86:99-105. 2010
    ..To assess the effects of fetal tracheal administration of VEGF on pulmonary maturation in a preterm rabbit model...
  58. ncbi VEGF: a modifier of the del22q11 (DiGeorge) syndrome?
    Ingeborg Stalmans
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Katholieke Universiteit Leuven, Leuven, Belgium
    Nat Med 9:173-82. 2003
    ..These genetic data in mouse, fish and human indicate that VEGF is a modifier of cardiovascular birth defects in the del22q11 syndrome...
  59. ncbi VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death
    Diether Lambrechts
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology and Department of Neurology, University Hospital Gasthuisberg, KU Leuven, Leuven, B 3000, Belgium
    Nat Genet 34:383-94. 2003
    ..These findings indicate that VEGF is a modifier of motoneuron degeneration in human ALS and unveil a therapeutic potential of Vegfa for stressed motoneurons in mice...
  60. ncbi Loss of placental growth factor protects mice against vascular permeability in pathological conditions
    Aernout Luttun
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Leuven B 3000, Belgium
    Biochem Biophys Res Commun 295:428-34. 2002
    ..These findings suggest that inhibition of PlGF might be an attractive tool to reduce vascular leakage in various diseases...
  61. ncbi Soluble VEGF isoforms are essential for establishing epiphyseal vascularization and regulating chondrocyte development and survival
    Christa Maes
    Laboratory of Experimental Medicine and Endocrinology, Katholieke Universiteit Leuven, Leuven, Belgium
    J Clin Invest 113:188-99. 2004
    ..These findings indicate that the insoluble VEGF(188) isoform is insufficient for establishing epiphyseal vascularization and regulating cartilage development during endochondral bone formation...
  62. ncbi Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease
    Sara Van de Veire
    Vesalius Research Center, KU Leuven, Leuven B 3000, Belgium
    Cell 141:178-90. 2010
    ..Further, we show that PlGF blockage inhibits vessel abnormalization rather than density in certain tumors while enhancing VEGF-targeted inhibition in ocular disease. Our findings warrant further testing of anti-PlGF therapies...
  63. ncbi Genetic studies on the role of proteinases and growth factors in atherosclerosis and aneurysm formation
    A Luttun
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, University of Leuven, Belgium
    Ann N Y Acad Sci 947:124-32; discussion 132-3. 2001
    ..In addition, a possible role for Gas6, the product of growth arrest-specific gene 6, in atherosclerotic lesion development is put into perspective...
  64. ncbi Generation of Pex5-loxP mice allowing the conditional elimination of peroxisomes
    M Baes
    Laboratory of Clinical Chemistry, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Leuven, Belgium
    Genesis 32:177-8. 2002
  65. ncbi VEGF and PlGF: two pleiotropic growth factors with distinct roles in development and homeostasis
    Marc Tjwa
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, University of Leuven, 3000, Leuven, Belgium
    Cell Tissue Res 314:5-14. 2003
    ..These new insights broaden the activity spectrum of these "angiogenic" growth factors, and may have therapeutic implications when using these growth factors for vascular and/or non-vascular purposes...
  66. ncbi Angiogenesis and lymphangiogenesis: highlights of the past year
    Aernout Luttun
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Leuven, Belgium
    Curr Opin Hematol 11:262-71. 2004
    ....
  67. ncbi Revascularization of ischemic tissues by PDGF-CC via effects on endothelial cells and their progenitors
    Xuri Li
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversitary Institute for Biotechnology (VIB, University of Leuven, Leuven, Belgium
    J Clin Invest 115:118-27. 2005
    ..Moreover, delivery of PDGF-CC enhanced postischemic revascularization of the heart and limb. Modulating the activity of PDGF-CC may provide novel opportunities for treating ischemic diseases...
  68. ncbi Cardia bifida, defective heart development and abnormal neural crest migration in embryos lacking hypoxia-inducible factor-1alpha
    Veerle Compernolle
    Flanders Interuniversitary Institute for Biotechnology, KU Leuven, Campus Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Cardiovasc Res 60:569-79. 2003
    ..We attempted to further characterize the underlying mechanisms resulting in abnormal cardiogenesis and defective angiogenesis in mice deficient for HIF-1alpha (HIF-1alpha(-/-))...
  69. ncbi Increased skeletal VEGF enhances beta-catenin activity and results in excessively ossified bones
    Christa Maes
    Laboratory of Experimental Medicine and Endocrinology, Department of Experimental Medicine, KU Leuven, Leuven, Belgium
    EMBO J 29:424-41. 2010
    ..Moreover, the finding that VEGF can modulate beta-catenin activity may have widespread physiological and clinical ramifications...
  70. ncbi VEGF-D deficiency in mice does not affect embryonic or postnatal lymphangiogenesis but reduces lymphatic metastasis
    Marta Koch
    Vesalius Research Centre, VIB, B 3000 Leuven, Belgium
    J Pathol 219:356-64. 2009
    ....
  71. ncbi Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels
    Christian Fischer
    Department for Transgene Technology and Gene Therapy, VIB, 3000, Leuven, Belgium
    Cell 131:463-75. 2007
    ..The efficacy and safety of alphaPlGF, its pleiotropic and complementary mechanism to VEGF(R)Is, and the negligible induction of an angiogenic rescue program suggest that alphaPlGF may constitute a novel approach for cancer treatment...
  72. ncbi Unconventional intronic splice site mutation in SCN5A associates with cardiac sodium channelopathy
    T Rossenbacker
    Centre for Transgene Technology and Gene Therapy, Flanders Interuniversitary Institute for Biotechnology, KULeuven, Campus Gasthuisberg, Herestraat 49, B 3000, Leuven, Belgium
    J Med Genet 42:e29. 2005
    ..The sodium channelopathies exhibit marked variation in clinical phenotypes. The mechanisms underlying the phenotypical diversity, however, remain unknown. Exonic SCN5A mutations can be detected in 20% of Brugada syndrome patients...
  73. ncbi Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice
    V A Ploplis
    Center for Transgene Technology and Gene Therapy, Vlaams Interuniversitair Instituut voor Biotechnologie, KU Leuven, Belgium
    Circulation 92:2585-93. 1995
    ..Circumstantial evidence suggests that the plasminogen/plasmin system plays a role in many biological processes, including hemostasis, cell migration, and development...
  74. ncbi Inactivation of the peroxisomal multifunctional protein-2 in mice impedes the degradation of not only 2-methyl-branched fatty acids and bile acid intermediates but also of very long chain fatty acids
    M Baes
    Laboratory of Clinical Chemistry and Laboratory of Pharmacology, K U Leuven, Herestraat 49 O N, B 3000 Leuven, Belgium
    J Biol Chem 275:16329-36. 2000
    ..The present data indicate that MFP-2 is not only essential for the degradation of 2-methyl-branched fatty acids and the bile acid intermediates di- and trihydroxycoprostanic acid but also for the breakdown of very long chain fatty acids...
  75. ncbi Meta-analysis of vascular endothelial growth factor variations in amyotrophic lateral sclerosis: increased susceptibility in male carriers of the -2578AA genotype
    D Lambrechts
    Center for Transgene Technology and Gene Therapy, KU Leuven, Leuven, Belgium
    J Med Genet 46:840-6. 2009
    ....
  76. ncbi A mouse model for Zellweger syndrome
    M Baes
    Laboratory of Clinical Chemistry, Kathlieke Universiteit Leuven, Belgium
    Nat Genet 17:49-57. 1997
    ..They displayed intrauterine growth retardation, were severely hypotonic at birth and died within 72 hours. Analysis of the neocortex revealed impaired neuronal migration and maturation and extensive apoptotic death of neurons...
  77. ncbi The diversity of endothelial cells: a challenge for therapeutic angiogenesis
    Edward M Conway
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, University of Leuven Gasthuisberg O and N, Herestraat 49, 3000 Leuven, Belgium
    Genome Biol 5:207. 2004
    ..Characterization of endothelial-cell diversity will facilitate the development of novel, highly specific and safe therapies for many diseases...
  78. ncbi Genetic dissection of tumor angiogenesis: are PlGF and VEGFR-1 novel anti-cancer targets?
    Aernout Luttun
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KULeuven, Campus Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Biochim Biophys Acta 1654:79-94. 2004
    ..Together, these insights may bring anti-angiogenic drugs closer from bench to bedside...
  79. ncbi Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way
    Peter Carmeliet
    Vesalius Research Center, VIB, KULeuven, Campus Gasthuisberg, Herestraat 49, Leuven, Belgium
    Nat Rev Clin Oncol 6:315-26. 2009
    ..This Review provides a conceptual framework in which molecular discoveries and principles are discussed in light of clinical opportunities to develop new antiangiogenic agents...
  80. ncbi The nuclear scaffold protein NIPP1 is essential for early embryonic development and cell proliferation
    Aleyde Van Eynde
    Division of Biochemistry, Center for Transgene Technology and Gene Therapy, Flanders Interuniversity, Institute for Biotechnology, Leuven, Belgium
    Mol Cell Biol 24:5863-74. 2004
    ..We conclude that NIPP1 is indispensable for early embryonic development and cell proliferation...
  81. ncbi Placental growth factor mediates mesenchymal cell development, cartilage turnover, and bone remodeling during fracture repair
    Christa Maes
    Laboratory of Experimental Medicine and Endocrinology, Katholieke Universiteit Leuven, Leuven, Belgium
    J Clin Invest 116:1230-42. 2006
    ..Therefore PlGF may potentially offer therapeutic advantages for fracture repair...
  82. ncbi Role of vascular endothelial growth factor receptor 1 in basal adhesion formation and in carbon dioxide pneumoperitoneum-enhanced adhesion formation after laparoscopic surgery in mice
    Carlos Roger Molinas
    Department of Obstetrics and Gynecology, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium
    Fertil Steril 82:1149-53. 2004
    ..To evaluate the role of vascular endothelial growth factor receptor-1 (VEGFR-1) in adhesion formation after laparoscopic surgery...
  83. ncbi Role of Gas-6 in adipogenesis and nutritionally induced adipose tissue development in mice
    Erik Maquoi
    Center for Molecular and Vascular Biology, KU Leuven, Leuven, Belgium
    Arterioscler Thromb Vasc Biol 25:1002-7. 2005
    ..A potential role of growth arrest-specific gene 6 (Gas-6) in energy storage in adipose tissue was investigated in murine models of obesity. Gas-6 is a ligand for the Axl, C-Mer, and Sky family of tyrosine kinase receptors...
  84. ncbi VEGF as a key mediator of angiogenesis in cancer
    Peter Carmeliet
    Center for Transgene Technology and Gene Therapy, Flander s Interuniversity Institute for Biotechnology, University of Leuven, Leuven, Belgium
    Oncology 69:4-10. 2005
    ..These characteristics mean that tumor blood flow is suboptimal, resulting in hypoxia and further VEGF production. This central role of VEGF in the production of tumor vasculature makes it a rational target for anticancer therapy...
  85. ncbi Life-threatening thrombosis in mice with targeted Arg48-to-Cys mutation of the heparin-binding domain of antithrombin
    Mieke Dewerchin
    Center for Transgene Technology and Gene Therapy, VIB, KULeuven Campus Gasthuisberg O and N, Herestraat 49, B 3000 Leuven, Belgium
    Circ Res 93:1120-6. 2003
    ....
  86. ncbi Role of vascular endothelial growth factor and placental growth factor in basal adhesion formation and in carbon dioxide pneumoperitoneum-enhanced adhesion formation after laparoscopic surgery in transgenic mice
    Carlos Roger Molinas
    Center for Surgical Technologies, Katholieke Universiteit Leuven, Leuven, Belgium
    Fertil Steril 80:803-11. 2003
    ..To evaluate the role of vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) in adhesion formation after laparoscopic surgery...
  87. ncbi Role of hypoxia inducible factors 1alpha and 2alpha in basal adhesion formation and in carbon dioxide pneumoperitoneum-enhanced adhesion formation after laparoscopic surgery in transgenic mice
    Carlos Roger Molinas
    Center for Surgical Technologies, Katholieke Universiteit Leuven, Leuven, Belgium
    Fertil Steril 80:795-802. 2003
    ..To evaluate the role of hypoxia inducible factors (HIFs) 1alpha and 2alpha in adhesion formation after laparoscopic surgery...
  88. ncbi Placental growth factor (PlGF) and its receptor Flt-1 (VEGFR-1): novel therapeutic targets for angiogenic disorders
    Aernout Luttun
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversitary Institute for Biotechnology, Leuven, Belgium
    Ann N Y Acad Sci 979:80-93. 2002
    ..Thus, PlGF and Flt-1 constitute potential candidates for therapeutic modulation of angiogenesis and inflammation...
  89. ncbi Role of the plasminogen system in basal adhesion formation and carbon dioxide pneumoperitoneum-enhanced adhesion formation after laparoscopic surgery in transgenic mice
    Carlos Roger Molinas
    Center for Surgical Technologies, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium
    Fertil Steril 80:184-92. 2003
    ..To evaluate the role of plasminogen activator inhibitor-1 (PAI-1), urokinase plasminogen activator (uPA), and tissue-type plasminogen activator (tPA) in adhesion formation after laparoscopic surgery...
  90. ncbi Loss of the cholesterol-binding protein prominin-1/CD133 causes disk dysmorphogenesis and photoreceptor degeneration
    Serena Zacchigna
    Vesalius Research Center, Vlaams Instituut voor Biotechnologie, Katholieke Universiteit Leuven, B 3000 Leuven, Belgium
    J Neurosci 29:2297-308. 2009
    ..These findings shed novel insight on how Prom-1 regulates neural retinal development and phototransduction in vertebrates...
  91. ncbi Regulation of angiogenesis by oxygen and metabolism
    Peter Fraisl
    Vesalius Research Center, Leuven, Belgium
    Dev Cell 16:167-79. 2009
    ..We will highlight advances in how oxygen and metabolism regulate angiogenesis as well as how angiogenic factors in turn also regulate metabolism...
  92. ncbi Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization
    Massimiliano Mazzone
    Vesalius Research Center, VIB Vlaams Instituut voor Biotechnologie, Leuven, Belgium
    Cell 136:839-51. 2009
    ..Inhibition of PHD2 may offer alternative therapeutic opportunities for anticancer therapy...
  93. ncbi Matrix-binding vascular endothelial growth factor (VEGF) isoforms guide granule cell migration in the cerebellum via VEGF receptor Flk1
    Carmen Ruiz de Almodovar
    Vesalius Research Center, Vlaams Instituut voor Biotechnologie, Vesalius Research Center, Katholieke Universiteit Leuven, Belgium
    J Neurosci 30:15052-66. 2010
    ..These findings identify a previously unknown role for VEGF in neuronal migration...
  94. ncbi Hungry for blood vessels: linking metabolism and angiogenesis
    Peter Fraisl
    Center for Transgene Technology and Gene Therapy, Katholieke Universiteit Leuven, Leuven, B 3000, Belgium
    Dev Cell 14:313-4. 2008
    ..These findings show that alterations in metabolic homeostasis are linked to angiogenesis, which raises exciting opportunities for novel proangiogenic and antiangiogenic therapies in various diseases...
  95. ncbi Gas6 promotes inflammation by enhancing interactions between endothelial cells, platelets, and leukocytes
    Marc Tjwa
    Department of Transgene Technology and Gene Therapy, Flanders Institute of Biotechnology VIB, Leuven, Belgium
    Blood 111:4096-105. 2008
    ..Thus, Gas6 amplifies EC activation, thereby playing a key role in enhancing the interactions between ECs, platelets, and leukocytes during inflammation...
  96. ncbi Angiogenesis in life, disease and medicine
    Peter Carmeliet
    Center of Transgene Technology and Gene Therapy, University of Leuven, Flanders Interuniversity Institute for Biotechnology VIB, B 3000 Leuven, Belgium
    Nature 438:932-6. 2005
    ..Angiogenesis research will probably change the face of medicine in the next decades, with more than 500 million people worldwide predicted to benefit from pro- or anti-angiogenesis treatments...
  97. ncbi Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited
    Sonja Loges
    Vesalius Research Center, VIB, B 3000 Leuven, Belgium
    Cancer Cell 15:167-70. 2009
    ..We discuss here how VEGF inhibitors can induce such divergent effects on primary tumor growth and metastasis...
  98. ncbi Similarities between angiogenesis and neural development: what small animal models can tell us
    Serena Zacchigna
    Department of Transgene Technology and Gene Therapy, VIB, Leuven, Belgium
    Curr Top Dev Biol 80:1-55. 2008
    ..In the first part of this chapter, we will discuss the more commonly used animal models; in the second part, the striking similarities occurring during the development of the vascular and the neural systems will be revised...
  99. ncbi A surrogate marker to monitor angiogenesis at last
    Martin Schneider
    The Flanders Interuniversity Institute for Biotechnology, The Center for Transgene Technology and Gene Therapy, KULeuven, Leuven, B-3000, Belgium
    Cancer Cell 7:3-4. 2005
    ..These findings highlight the potential usefulness of CEPs as a surrogate marker to monitor and adjust antiangiogenic therapy...
  100. ncbi Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice
    Stephane Heymans
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute, Herestraat 49, B 3000 Leuven, Belgium
    Am J Pathol 166:15-25. 2005
    ..Deficiency of MMP-9 had an intermediate effect. These findings suggest that the use of u-PA- or MMP-inhibitors might preserve cardiac pump function in LV pressure overloading...
  101. ncbi Role and therapeutic potential of VEGF in the nervous system
    Carmen Ruiz de Almodovar
    The Vesalius Research Center, KU Leuven and VIB, Leuven, Belgium
    Physiol Rev 89:607-48. 2009
    ..We describe the molecular properties of VEGF and its receptors and review the current knowledge of its different functions and therapeutic potential in the nervous system during development, health, disease and in medicine...